In a Phase III study, Celgene's ABRAXANE® (NAB-PACLITAXEL), currently approved for breast and lung cancer, has been found to improve overall survival for patients with advanced pancreatic cancer.
A Phase III study of Abraxane (nanoparticle albumin-bound -'nab' - paclitaxel) in combination with gemcitabine in treatment-naive patients with advanced pancreatic cancer met its primary endpoint of overall survival, compared to patients receiving gemcitabine alone.
The full extent of the improved survival and data on progression free response and side effects is not yet available. Full results from the trial, which included 861 patients, will be presented at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium in January.
Alex Ford, CEO, Pancreatic Cancer UK, comments, "We are delighted to hear that Celgene's study has reached its survival endpoint, as new treatment options for advanced pancreatic cancer are urgently needed. We hope that the study shows really positive results when the full data is available in January.
"If the full results show a real benefit for this patient group then we will be calling for this treatment to be made available to patients in the UK as soon as possible."
Source: Celgene press release